Company Overview and News
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C ALA.PR.B ALA.PR.A ALA.PR.I MFC ATGFF ALA.PR.G 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L
June 13 (Reuters) - Canadian utility AltaGas Ltd said on Wednesday it would sell a 35 percent stake in three hydroelectric projects in Northwest British Columbia for C$922 million ($707.87 million) to help fund its acquisition of U.S.-based WGL Holdings Inc.
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C WGL ALA.PR.B ALA.PR.A ALA.PR.I MFC ALA.PR.G ATGFF 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L
June 13 (Reuters) - Canadian utility AltaGas Ltd said on Wednesday it would sell a 35 percent stake in the Northwest British Columbia Hydro Electric Facilities for C$922 million ($707.87 million).
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C WGL ALA.PR.B ALA.PR.A ALA.PR.I MFC ATGFF ALA.PR.G 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L
WGL Holdings, Inc (WGL - Free Report) announced the receipt of approval from Maryland Public Service Commission for its merger with AltaGas Ltd. (ALA.TO). The merger is valued at $4.5 billion. Subject to approval from the Public Service Commission of District of Columbia, the merger, which was announced on Jan 25, 2017, is expected to be completed by the first half of 2018. Approval Subject to Conditions Maryland Public Service Commission’s approval for the merger of the complementary energy companies is subject to the fulfillment of certain conditions.
WFCNP SCG ALA.PR.U WGL WFC.PRL WFC.PRJ WFC.PRT WFC.PRR ATGFF WFC.PRQ WFC.PRP WFC.PRO UBS WFC.PRN SCU UBS.PRDCL WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS NJR ALA.PR.B ALA.PR.A ALA.PR.I ALA.PR.G ALA.PR.E ALA ULSGF
CALGARY, Alberta, April 03, 2018 (GLOBE NEWSWIRE) -- Birchcliff Energy Ltd. (“Birchcliff”) (TSX:BIR) and AltaGas Ltd. (“AltaGas”) (TSX:ALA) are pleased to announce that they have entered into a definitive agreement for a long-term natural gas processing arrangement (the “Processing Arrangement”) at AltaGas’ deep-cut sour gas processing facility located in Gordondale, Alberta (the “Gordondale Facility”).
ALA.PR.I BIR ATGFF ALA.PR.G BIREF ALA.PR.U ALA.PR.E ALA.PR.B ALA.PR.A ALA
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...